Advertisement

Multiple Myeloma and Plasmacytoma

  • Lauren Boreta
  • Steve E. Braunstein
Chapter
First Online:

Abstract

This chapter will discuss radiation therapy for multiple myeloma and solitary plasmacytoma.

Keywords

Multiple myeloma Plasmacytoma 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank Thomas T. Bui, MD; Kavita Mishra, MD, MPH; and Mack Roach III, MD, for their work on the prior edition of this chapter.

References

  1. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85:2305–14.CrossRefGoogle Scholar
  2. Catell D, Kogen Z, Donahue B, et al. Multiple myeloma of an extremity: must the entire bone be treated? Int J Radiat Oncol Biol Phys. 1998;40(1):117–9.CrossRefGoogle Scholar
  3. Creach CM, Foote RL, Netten-Wittich MA, et al. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;73(3):789–94.CrossRefGoogle Scholar
  4. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–54.CrossRefGoogle Scholar
  5. Frassica DA, Frassica FJ, Schray MF, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):43–8.CrossRefGoogle Scholar
  6. Hirsch AE, Jha RM, et al. The use of vertebral augmentation and external beam radiation therapy in the multimodal management of malignant vertebral compression fractures. Pain Physician. 2011;14(5):447–58.PubMedGoogle Scholar
  7. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology. 2000;14(1):100–11.Google Scholar
  8. Kim P, Hicks RJ, Wirth A, et al. Impact of (18)F-Fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2008;74:740–6.CrossRefGoogle Scholar
  9. Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P. Prediction of high- and low-risk multiple myeloma based on gene expression and the international staging system. Blood. 2015 Oct 22;126(17):1996–2004.CrossRefGoogle Scholar
  10. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347.CrossRefGoogle Scholar
  11. Lee JW, Lee JE. Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. Radiat Oncol J. 2016;34(1):59–63.CrossRefGoogle Scholar
  12. Moreau P, Facon T, Attal M, et al. Comparison fo 200mg/m2 mephalan and 8 Gy Tbi plus 140 mg/m2 mephalan as conditioning regiments for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99(3):731–5.CrossRefGoogle Scholar
  13. Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488–93.CrossRefGoogle Scholar
  14. Nau K, Lewis W. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2008;78(7):853–9. 860PubMedGoogle Scholar
  15. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–7.CrossRefGoogle Scholar
  16. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from the IMWG. J Clin Oncol. 2015;33:2863–9.CrossRefGoogle Scholar
  17. Terpos E, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma related bone disease. J Clin Oncol. 2013;20(June):2347–57.CrossRefGoogle Scholar
  18. Rajkumar V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.CrossRefGoogle Scholar
  19. Sasaki R, Yasuda K, Abe E, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):626–34.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation Oncology, University of California San FranciscoSan FranciscoUSA

Personalised recommendations

Cite chapter